Lilly announces three acquisitions to build infectious disease portfolio
Agreements with Curevo, LimmaTech Biologics and Vaccine Company address viral pathogens linked to long-term neurological and oncological risk,…
One-and-Done Heart Disease Prevention? Scientists Show It May Be Possible.
In a small, preliminary study, an experimental gene-editing treatment dramatically lowered cholesterol levels, perhaps permanently, after just one…
Lilly’s triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial
In TRIUMPH-1, participants on 12 mg retatrutide lost an average of 70.3 lbs (28.3%) over 80 weeks with…
Experimental Drug Yields Dramatic Weight Loss
An experimental shot helped participants in a large trial lose far more weight than obesity drugs already on…
Lilly to acquire Kelonia Therapeutics to advance in vivo CAR-T cell therapies
Kelonia’s lead program, KLN-1010, is a potentially first-in-class lentiviral in vivo CAR-T therapy currently in Phase 1 for…
Lilly announces more than $1.2 billion investment in Puerto Rico facility to boost oral medicine manufacturing capacity in the United States
Company plans to create 100 manufacturing jobs and up to 1,000 construction jobs INDIANAPOLIS, Oct. 29, 2025 /PRNewswire/…
Lilly partners with NVIDIA to build the industry’s most powerful AI supercomputer, supercharging medicine discovery and delivery for patients
New AI capabilities will help scientists identify, optimize and validate new molecules Additional applications include manufacturing, medical imaging…
Lilly announces roster of Team USA athletes for the Olympic and Paralympic Games Milano Cortina 2026, pledges to translate U.S. Olympic and Paralympic milestones into meaningful community impact
INDIANAPOLIS, Oct. 28, 2025 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced its roster of Team…
Lilly declares fourth-quarter 2025 dividend
INDIANAPOLIS, Oct. 27, 2025 /PRNewswire/ — The board of directors of Eli Lilly and Company (NYSE: LLY) has…
Lilly to Acquire Adverum Biotechnologies
Adverum’s lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet…